|drug3420||Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE) Wiki||1.00|
|drug2507||Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a randomized trial of home-based exercises versus control for older adults during the COVID-19 pandemic. The hypothesis is that participation in a home-based program will reduce the risk of adverse effects of physical distancing by decreasing patient-reported disability, improving mental health and avoiding hospitalization or institutionalization for vulnerable older people
Description: The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) will be used . It is a patient-reported disability scale that assesses limitations in six major life domains - cognition, mobility, self-care, social interaction, life activities and participation in society. Participants will report if they have had no difficulty, mild difficulty, moderate difficulty, severe difficulty or extreme difficulty (simply cannot do) with the items listed.Measure: Patient-reported disability 90 days after enrollment Time: Assessing change in score from baseline data collection to 90 days from enrollment
Description: The Patient Health Questionnaire-9 item (PHQ-9) and the Generalized Anxiety Disorder 7-item (GAD-7) are validated tools for diagnosing anxiety and depression.Measure: Mental Health Time: Assessing change in the participants GAD-7 score from baseline to monthly scores for 12 months.
Description: Step count using pedometerMeasure: Function Time: Monthly step count from enrollment to monthly step counts for 12 months from enrollment.
Description: The EQ-5D-5L is a validated instrument with Canadian valuation statistics and national use, which informs incremental cost per quality-adjusted life year gained.Measure: Health-related quality of life Time: Assessing change in the participants EQ-5D-5L score from baseline to monthly scores for 12 months.
Description: The Clinical Frailty Scale (CFS) provides a global assessment of frailty.Measure: Frailty Time: Assessing change in the participants CFS score from baseline to monthly scores for 12 months.
Description: All deaths and death dates will be identified via chart review or telephone call.Measure: All-cause mortality. Time: From enrollment to 12 months after enrollment.
Description: Falls, cardiac or respiratory complications and unplanned healthcare encounters will be collected during the exercise treatment period for the exercise group. For the control group, participants will be asked if they experienced any falls since the time of enrollment up until the day before surgery. Unplanned healthcare encounters will also be collected during the time of enrollment to the final day of the exercise intervention for the intervention group through chart review.Measure: Safety [Adverse Events] Time: Assessing frequency of, or change in any safety events from enrollment up to 90 days from enrollment between the exercise group and control group.
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports